Durrant L G, Robins R A, Ballantyne K C, Austin E B, Baldwin R W
Cancer Research Campaign Laboratories, University of Nottingham, United Kingdom.
Cancer Immunol Immunother. 1990;31(4):226-30. doi: 10.1007/BF01789173.
The development of human antibodies recognising mouse immunoglobulins represents an obstacle to effective antibody therapy. This study shows that patients produce modest titres of antibodies (predominantly anti-mouse rather than anti-idiotypic) after a single low-dose injection for immunoscintigraphy, suggesting that repeated imaging with the same or a different antibody could be a problem. Fusion of the lymphocytes from a patient who had been imaged twice previously resulted in a monoclonal antibody that specifically binds to an IgG2b isotypic determinant. Anti-IgG2b antibodies predominated in this patient's serum. Production of human monoclonal antibodies from patients given mouse monoclonal antibodies not only allows a finer dissection of the immune repertoire but also provides possible reagents for controlling the human anti-(mouse Ig) response, for selection of class-switch variants of mouse monoclonal antibodies and enhancing tumour imaging.
识别小鼠免疫球蛋白的人源抗体的产生是有效抗体治疗的一个障碍。这项研究表明,患者在接受单次低剂量注射用于免疫闪烁成像后会产生中等滴度的抗体(主要是抗小鼠而非抗独特型抗体),这表明使用相同或不同抗体进行重复成像可能会有问题。对一名此前已进行过两次成像的患者的淋巴细胞进行融合,产生了一种特异性结合IgG2b同种型决定簇的单克隆抗体。该患者血清中以抗IgG2b抗体为主。给患者注射小鼠单克隆抗体后产生人源单克隆抗体,不仅能更精细地剖析免疫库,还能提供可能的试剂来控制人抗(小鼠Ig)反应、选择小鼠单克隆抗体的类别转换变体以及增强肿瘤成像。